-
Electronic (PDF)
-
Site License
-
Enterprisewide
Abiogen Pharma S.p.A. - Product Pipeline Review - H2 2011
Global Markets Direct, September 2011, Pages: 27
Abiogen Pharma S.p.A. – Product Pipeline Review – H2 2011
Summary
Global Market Direct’s pharmaceuticals report, “Abiogen Pharma S.p.A. – Product Pipeline Review – H2 2011” provides data on the Abiogen Pharma S.p.A.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Abiogen Pharma S.p.A.’s corporate website, SEC filings, investor presentations and featured press releases, both from Abiogen Pharma S.p.A. and industry–specific third party sources, put together by Global Markets Direct’s team.
Scope
- Abiogen Pharma S.p.A. - Brief Abiogen Pharma S.p.A. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Abiogen Pharma S.p.A. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Abiogen Pharma S.p.A. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Abiogen Pharma S.p.A.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Abiogen Pharma S.p.A.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Abiogen Pharma S.p.A. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Abiogen Pharma S.p.A.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Abiogen Pharma S.p.A..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Abiogen Pharma S.p.A. and identify potential opportunities in those areas.
List of Tables
List of Figures
Abiogen Pharma S.p.A. Snapshot
Abiogen Pharma S.p.A. Overview
Key Information
Key Facts
Abiogen Pharma S.p.A. – Research and Development Overview
Key Therapeutic Areas
Abiogen Pharma S.p.A. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Abiogen Pharma S.p.A. – Pipeline Products Glance
Abiogen Pharma S.p.A. Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Abiogen Pharma S.p.A.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Abiogen Pharma S.p.A. – Drug Profiles
ABIO 09/01
Product Description
Mechanism of Action
R&D Progress
Combotox N97A
Product Description
Mechanism of Action
R&D Progress
cUV3
Product Description
Mechanism of Action
R&D Progress
IMTOX 22
Product Description
Mechanism of Action
R&D Progress
Abiogen Pharma S.p.A. – Pipeline Analysis
Abiogen Pharma S.p.A. – Pipeline Products by Therapeutic Class
Abiogen Pharma S.p.A. - Pipeline Products By Target
Abiogen Pharma S.p.A. – Pipeline Products by Molecule Type
Abiogen Pharma S.p.A. - Dormant Projects
Abiogen Pharma S.p.A. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Apr 28, 2010: Abiogen: EMEA Grants Orphan Drug Designation for a Treatment of Ovarian Cancer
Jul 23, 2003: BTG Licenses BTG 1675A To Abiogen Pharma S.p.A
Jul 23, 2003: BTG Licenses New Class Of Psychiatric Drugs To Abiogen Pharma S.p.A
Apr 14, 2005: Abiogen Pharma's New Cell Therapy Starts a Clinical Phase I/II in Peritoneal Carcinosis
Financial Deals Landscape
Abiogen Pharma S.p.A., Deals Summary, 2004 to 2011
Abiogen Pharma S.p.A. Detailed Deal Summary
Licensing Agreements
Samaritan Pharmaceuticals Enters Into Licensing Agreement With Abiogen Pharma
Cancer Research Technology Enters Into Licensing Agreement With Abiogen
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Abiogen Pharma S.p.A. – Pipeline by Therapy Area and Indication, H2 2011
Abiogen Pharma S.p.A. – Pipeline by Stage of Development, H2 2011
Abiogen Pharma S.p.A. – Monotherapy Products in Pipeline, H2 2011
Abiogen Pharma S.p.A. - Phase I, H2 2011
Abiogen Pharma S.p.A. - Pipeline By Therapeutic Class, H2 2011
Abiogen Pharma S.p.A. - Pipeline By Target, H2 2011
Abiogen Pharma S.p.A. – Pipeline By Molecule Type, H2 2011
Abiogen Pharma S.p.A. - Dormant Developmental Projects, 2010
Abiogen Pharma S.p.A., Other Locations
Abiogen Pharma S.p.A., Deals Summary, 2004 to 2011
List of Figures
Abiogen Pharma S.p.A. – Pipeline by Therapy Area and Indication, H2 2011
Abiogen Pharma S.p.A. – Pipeline by Stage of Development, H2 2011
Abiogen Pharma S.p.A. – Monotherapy Products in Pipeline, H2 2011
Abiogen Pharma S.p.A. – Pipeline By Therapeutic Class, H2 2011
Abiogen Pharma S.p.A. - Pipeline By Target, H2 2011
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW6
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
